secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2022-08-10T23:59:59+00:00
Accession:  0001104659-22-088622
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q2 revenue $10.4M (+38% YoY); FY2022 guidance $42-45M
--------------------------------------------------------------

- Q2 revenue of $10.4M, up 38% YoY; OviTex revenue +22%, OviTex PRS +87%.
- Net loss widened to $12.7M from $8.3M; operating loss $10.2M vs $7.3M.
- FY2022 revenue guidance $42-45M (43-53% growth); COVID could impact.
- Cash $27.7M at June 30; secured up to $50M debt facility from MidCap Financial.
- Entered GPO contract with Premier Inc. covering ~4,400 hospitals, effective October 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922088622/0001104659-22-088622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922088622/tm2223031d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-088622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer